<DOC>
	<DOCNO>NCT00052728</DOCNO>
	<brief_summary>RATIONALE : Tipifarnib may stop growth tumor cell block enzymes necessary tumor cell growth . Tamoxifen may fight breast cancer block use estrogen . Combining tipifarnib tamoxifen may effective treatment metastatic breast cancer . PURPOSE : This phase II trial study well give tipifarnib together tamoxifen work treat woman metastatic breast cancer .</brief_summary>
	<brief_title>Tipifarnib Plus Tamoxifen Treating Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose tipifarnib administer tamoxifen woman hormone receptor-positive metastatic breast cancer ( Phase I close accrual effective 10/23/2003 ) . - Determine acute chronic toxicity regimen patient . - Determine pharmacokinetics regimen patient . - Determine response rate time progression patient treat regimen . OUTLINE : This open-label study tipifarnib ( Phase I close accrual effective 10/23/2003 ) . Patients stratify accord benefit prior hormonal therapy ( yes v ) ( phase II ) . - Phase I ( close accrual effective 10/23/2003 ) : Patients receive oral tipifarnib twice daily day 1-21 . Patients also receive oral tamoxifen daily day 8-18 ( course I ) day 1-28 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Once MTD determine , additional patient accrue treated dose level phase II portion study . Patients follow 30 day . PROJECTED ACCRUAL : A total 9-12 patient accrued phase I portion study ( Phase I close accrual effective 10/23/2003 ) . A total 27-40 patient accrue phase II portion study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic ( stage IV ) breast cancer Evidence disease progression Measurable disease Must previously treat least 1 hormonal therapy either aromatase inhibitor estrogen receptor ( ER ) modulate drug adjuvant metastatic set meet 1 follow criterion : Hormoneresponsive disease : Stable disease ( recurrence progression least 6 month ) Objective response Hormonenonresponsive disease : No stable disease No objective response Previously treat CNS disease allow provide patient life expectancy least 3 month ( phase I patient ) ( Phase I close accrual effective 10/23/2003 ) No CNS metastasis ( phase II patient ) Hormone receptor status : ER and/or progesterone receptor positive NOTE : As 1 % positive cell consider positive PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status Zubrod 01 Life expectancy See Disease Characteristics Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2.0 mg/dL ( unless evidence Gilbert 's disease ) SGOT SGPT less 3 time upper limit normal ( unless liver involvement tumor ) Renal Creatinine great 1.5 mg/dL Other Not pregnant Negative pregnancy test Fertile patient must use effective nonhormonal contraception 2 month study participation No medical psychiatric condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No 2 prior chemotherapy regimens metastatic disease ( phase II patient ) No limitation prior neoadjuvant adjuvant regimen At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) Endocrine therapy See Disease Characteristics At least 6 month since prior tamoxifen Concurrent stable dose steroid allow ( phase I patient ) ( Phase I close accrual effective 10/23/2003 ) Radiotherapy No concurrent radiotherapy Surgery Concurrent surgery allow provide need surgery due disease progression Other Recovered prior therapy No prior warfarin No concurrent cytochrome p450inducing anticonvulsant No concurrent anticancer therapy Concurrent bisphosphonates bone metastasis allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2005</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>